FDAAA Impact Analysis: Year One
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
If you want to market a new pharmaceutical or vaccine ingredient in the U.S., you should consult a copy of the 2007 Food & Drug Administration Amendments Act
You may also be interested in...
The REMS Ramp Up: FDA Using New Safety Tools More Frequently In Year Two
FDA has invoked formal Risk Evaluation & Mitigation Strategy Authority almost as often the last five months as it did in the first full year of the program. Use of more intense REMS-those with communication plans and elements to assure safe use-is increasing even faster, and indications are this is the leading edge of a wave of new restrictive programs. REMS unquestionably delay approvals, FDA officials acknowledge-and yet, more drugs are coming out of FDA.
Waking Up to REMS (Part 1): Don't Believe the Lack of Hype
FDA's top management can't be accused of overstating the importance of the agency's new drug safety tools. But sponsors need to wake up to the reality: the REMS are a critical fact of drug development and marketing.
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.